Chris Ryan

1 week ago | cancernetwork.com | Chris Ryan

Ponatinib (Iclusig) was associated with higher rates of deep molecular responses and improved survival in patients with newly diagnosed, Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL) who were positive for minimal residual disease (MRD) after induction and continued treatment beyond cycle 3, according to findings from a post hoc analysis of the phase 3 PhALLCON trial (NCT03589326) shared at the 2025 EHA Congress.1 Data showed that 56% of patients in the ponatinib arm...

1 week ago | cgtlive.com | Matthew Ku |Noah Stansfield |Ashling Wahner |Chris Ryan

Data from a phase 1b clinical trial (NCT05421663) evaluating Johnson & Johnson’s JNJ-90014496, a CD19 and CD20-directed bispecific chimeric antigen receptor (CAR) T-cell therapy, were presented at the European Hematology Association (EHA) 2025 Congress, held June 12 to 15, both virtually and in Milan, Italy.

1 week ago | cgtlive.com | Matthew Ku |Ashling Wahner |Chris Ryan

This video originally appeared on our sister site, OncLive®. "Overall, only 7 patients, or 28% of the recommended phase 2 dose group, reported a serious treatment emergent adverse event."Johnson & Johnson’s JNJ-90014496, a CD19 and CD20-directed bispecific chimeric antigen receptor (CAR) T-cell therapy, is currently being evaluated for the treatment of relapsed/refractory (r/r) large B-cell lymphoma (LBCL) in a phase 1b clinical trial (NCT05421663).

2 weeks ago | cancernetwork.com | Chris Ryan

Efficacy and safety were reported in patients with estrogen receptor (ER)–positive, HER2-negative breast cancer previously managed with CDK4/6 inhibition plus endocrine therapy following treatment with elacestrant (Orserdu) plus everolimus (Afinitor) or ribociclib (Kisqali), according to findings from the phase 1b/2 ELEVATE trial (NCT05563220) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.1 Findings from the phase 1b portion of the study presented at the...

2 weeks ago | cancernetwork.com | Chris Ryan

Efficacy and safety were reported in patients with estrogen receptor (ER)–positive, HER2-negative breast cancer previously managed with CDK4/6 inhibition plus endocrine therapy following treatment with elacestrant (Orserdu) plus everolimus (Afinitor) or ribociclib (Kisqali), according to findings from the phase 1b/2 ELEVATE trial (NCT05563220) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.1 Findings from the phase 1b portion of the study presented at the...